About

QCELL is a deep-tech, spin-off company of the Technical University of Crete, in the field of imaging medical device technology. The company was founded in June 2016 by Professor Costas Balas, and it is based in Chania, Crete, Greece.

Solution & Product

QCELL is at the forefront of the biophotonic hyperspectral imaging technology sector. The Company’s groundbreaking patented innovations change the future of endoscopy and clinical microscopy and propels the firm to be the leader in their perspective AI-powered, Spectral Imaging transformation. This unique technology delivers pathology maps, in vivo, instantly and noninvasively, minimizing or even eliminating the need for invasive biopsies.

Innovation & Scalability

Inaugurating the next generation of medical optical imaging devices, QCELL has lunched to markets three, CE-Marked, Smart Spectral View Imagers, dedicated to dermoscopy, endoscopy and colposcopy. The Spectral View imaging platform is directly adaptable to all kinds of medical “scopes” (dermoscopes, endoscopes (more than 20 variants/disciplines), colposcopes etc.), defining an addressable market $40bn @ 7.5% Compound Annual Growth Rate (CAGR).

Traction & achievements

QCELL holds several issued patents in USA, EU, China, Korea, Japan, etc., protecting its proprietary Spectral View platform imaging technology and has recently launched three CE-Marked products in global markets, has conducted clinical trials and has published several, high profile technical and clinical papers. The company conducts in-house manufacturing, certified according to medical ISO 13485, and is listed to the European medical device manufactures Data Base (EUDAMED).

Team & Why Us

QCELL’s Founder and CEO is Prof. Costas Balas, a recognised expert and innovator in biophotonics and hyperspectral imaging and a serial founder of MedTechs offering of life-saving, FDA-approved products, commercialised worldwide. Prof. Costas Balas attracted multimillion-euro funding from grants and VCs, designed and led large international clinical trials and FDA approval, authored more than 100 scientific publications and granted several international patents and received innovation awards. His achievements have been showcased in The Economist, The Times, Research Outreach, Science a Vie, Nature Oncology. The business leadership is supported by a highly skilled multidisciplinary team of scientists, engineers and operations experts.

Funding Needs

QCELL has accomplished all these high added value milestones at its seed funding stage, being also self-funded through sales and grants. The company currently implements an ambitious BP towards global expansion.